VEGFA and melanoma: Univariate and multivariable logistic regression analysis was performed to identify the association between the potential risk factors and the occurrence of immune-related adverse events (irAEs).<h4>Results</h4>A total of 508 advanced melanoma patients receiving PD-1 monotherapy (n = 181), PD-1 + tyrosine kinase inhibitors (TKI, n = 131), PD-1 + anti-vascular endothelial growth factor (anti-VEGF, n = 56), PD-1 + interferon Alfa-1b (IFN-α1b, n = 99) and PD-1 + IFN-α1b + TKI (n = 41) were included.